Alimera Sciences, Inc. (NASDAQ:ALIM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “

A number of other equities research analysts also recently commented on the company. ValuEngine raised Alimera Sciences from a “sell” rating to a “hold” rating in a report on Thursday. Cowen and Company reissued a “buy” rating and issued a $3.00 target price on shares of Alimera Sciences in a report on Tuesday. HC Wainwright set a $5.00 target price on Alimera Sciences and gave the company a “buy” rating in a report on Tuesday. Finally, Rodman & Renshaw began coverage on Alimera Sciences in a report on Thursday, April 27th. They issued a “buy” rating and a $4.00 target price for the company. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $3.38.

Shares of Alimera Sciences (ALIM) remained flat at $1.50 during midday trading on Thursday. The company’s stock had a trading volume of 289,406 shares. The stock’s market capitalization is $97.35 million. The firm’s 50-day moving average is $1.40 and its 200-day moving average is $1.33. Alimera Sciences has a 52 week low of $1.01 and a 52 week high of $2.40.

Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $6.62 million during the quarter, compared to the consensus estimate of $8.80 million. During the same period in the prior year, the business posted ($0.22) earnings per share. The business’s revenue for the quarter was up 14.1% compared to the same quarter last year. Equities analysts predict that Alimera Sciences will post ($0.21) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at

A hedge fund recently bought a new stake in Alimera Sciences stock. Kennedy Capital Management Inc. acquired a new position in Alimera Sciences, Inc. (NASDAQ:ALIM) during the first quarter, according to its most recent disclosure with the SEC. The fund acquired 333,248 shares of the biopharmaceutical company’s stock, valued at approximately $467,000. Hedge funds and other institutional investors own 43.60% of the company’s stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Get a free copy of the Zacks research report on Alimera Sciences (ALIM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with's FREE daily email newsletter.